02099nas a2200205 4500000000100000008004100001653000800042653001200050100001400062700001300076700002500089700001200114700001200126700001100138700001400149700001400163245007000177520163200247022001401879 2019 d10aUSA10aleprosy1 aBezalel S1 aOnajin O1 aGonzalez-Santiago TM1 aPatel R1 aPritt B1 aVirk A1 aGibson LE1 aPeters MS00aLeprosy in a Midwestern dermatology clinic: Report of 9 patients.3 a
OBJECTIVE: To describe the clinical features and epidemiology of leprosy in patients evaluated in a Midwestern dermatology clinic.
PATIENTS AND METHODS: We performed a retrospective review of clinical and laboratory data from patients with leprosy who were evaluated in the Department of Dermatology at Mayo Clinic in Rochester, Minnesota, from January 1, 1994, through December 31, 2017.
RESULTS: Nine patients, 7 male and 2 female, were identified, ranging in age from 15 to 63 years (mean age, 38 years). Six of the 9 patients (67%) were foreign-born: 3 from Oceania (2 from Micronesia and 1 from Guam), 1 from Southeast Asia (Indonesia), and 2 from Mexico. Three patients were born in the United States. All 9 patients presented with skin lesions (granulomatous histopathologic type), and 8 had neuropathy. Leprosy was multibacillary in 8 patients and paucibacillary in 1. Two patients experienced a type 1 treatment reaction, and 5 had type 2 reactions. Three of the 9 patients had speciation by polymerase chain reaction (Mycobacterium leprae in 2 and Mycobacterium lepromatosis in 1).
CONCLUSION: Despite its rarity in the United States, leprosy should be considered in the differential diagnosis when evaluating both foreign- and US-born patients with granulomatous dermatitis and peripheral neuropathy. Because M lepromatosis was not identified until 2008 and requires polymerase chain reaction for diagnosis, the incidence of this species among patients with leprosy diagnosed in earlier years is unknown.
a1942-5546